scholarly journals Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study

2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Katharine Barnard-Kelly ◽  
Clare A. Whicher ◽  
Hermione C. Price ◽  
Peter Phiri ◽  
Shanaya Rathod ◽  
...  
Keyword(s):  
Mental Illness ◽  
Severe Mental Illness ◽  
Healthcare Professionals ◽  
First Episode Psychosis ◽  
First Episode ◽  
Schizoaffective Disorders ◽  
Episode Psychosis ◽  
Treatment Of Obesity

Abstract Background People with severe mental illness are two to three times more likely to be overweight or have obesity than the general population and this is associated with significant morbidity and premature mortality. Liraglutide 3 mg is a once daily injectable GLP-1 receptor agonist that is licensed for the treatment of obesity in the general population and has the potential to be used in people with severe mental illness. Aims To record the expectations and experiences of people with schizophrenia, schizoaffective disorders or first episode psychosis taking daily liraglutide 3 mg injections in a clinical trial for the treatment of obesity. To seek the views of healthcare professionals about the feasibility of delivering the intervention in routine care. Methods Qualitative interviews were undertaken with a purposive sub-sample of people with schizophrenia, schizoaffective disorders or first episode psychosis with overweight or obesity who were treated with a daily injection of liraglutide 3 mg in a double-blinded, randomised controlled pilot study evaluating the use of liraglutide for the treatment of obesity. Interviews were also conducted with healthcare professionals. Results Seventeen patient participants were interviewed. Sixteen took part in the baseline interview, eight completed both baseline and follow-up interviews, and one took part in follow-up interview only. Mean interview duration was thirteen minutes (range 5-37 min). Despite reservations by some participants about the injections before the study, most of those who completed the trial reported no challenges in the timing of or administering the injections. Key themes included despondency regarding prior medication associated weight gain, quality of life impact of weight loss, practical aspects of participation including materials received and clinic attendance. Healthcare professionals reported challenges with recruitment, however, overall it was a positive experience for them and for participants. Conclusion Liraglutide appears to be an acceptable therapy for obesity in this population with limited side effects. The quality of life benefits realised by several intervention participants reinforce the biomedical benefits of achieved weight loss.

scholarly journals Liraglutide and the Management of Overweight and Obesity in People with Severe Mental Illness: Qualitative Sub-Study

2021 ◽  
Author(s):  
Katharine Barnard-Kelly ◽  
Clare A Whicher ◽  
Hermione Price ◽  
Peter Phiri ◽  
Carolyn Asher ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Weight Loss ◽  
Healthcare Professionals ◽  
First Episode Psychosis ◽  
First Episode ◽  
Schizoaffective Disorders ◽  
Episode Psychosis ◽  
Treatment Of Obesity

Abstract Background: People with severe mental illness are two to three times more likely to be overweight or have obesity than the general population and this is associated with significant morbidity and premature mortality. Liraglutide 3mg is a once daily injectable GLP-1 receptor agonist that is licensed for the treatment of obesity in the general population and has the potential to be used in people with severe mental illness.Aim: To gain an insight into the feasibility and acceptability of using liraglutide 3mg for the treatment of obesity in people with schizophrenia, schizoaffective disorders or first episode psychosis. Methods: Qualitative interviews were undertaken with a purposive sub-sample of people with schizophrenia, schizoaffective disorders or first episode psychosis and healthcare professionals with overweight or obesity who were treated with a daily injection of liraglutide 3mg in a double-blinded, randomised controlled pilot study evaluating the use of liraglutide for the treatment of obesity. Interviews were also conducted with healthcare professionals.Results: Seventeen patient participants were interviewed. Sixteen took part in the baseline interview, eight completed both baseline and follow-up interviews, and one took part in follow-up interview only. Mean interview duration was thirteen minutes (range 5-37 minutes). Despite reservations by some participants about the injections before the study, most of those who completed the trial reported no challenges in the timing of or administering the injections. Key themes included despondency regarding prior medication associated weight gain, quality of life impact of weight loss, practical aspects of participation including materials received and clinic attendance. Healthcare professionals reported challenges with recruitment, however, overall it was a positive experience for them and for participants. Conclusion: Liraglutide appears to be an acceptable therapy for obesity in this population with limited side effects. The quality of life benefits realised by several intervention participants reinforce the biomedical benefits of achieved weight loss.

Perceived stress, social functioning and quality of life in first‐episode psychosis: A 1‐year follow‐up study

2020 ◽  
Author(s):  
Laura Ortega ◽  
Itziar Montalvo ◽  
Rosa Monseny ◽  
Maria Dolors Burjales‐Martí ◽  
Lourdes Martorell ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Social Functioning ◽  
Perceived Stress ◽  
First Episode Psychosis ◽  
First Episode ◽  
Follow Up Study ◽  
Episode Psychosis

A prospective follow-up of quality of life, wellbeing, side effects and compliance in the treatment of first episode psychosis

2003 ◽  
Vol 60 (1) ◽  
pp. 329
Author(s):  
T. Taylor ◽  
M. O'Toole ◽  
J. Walters ◽  
R. Ohlsen ◽  
R. Purvis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis

Poster #242 CLINICAL AND MORPHOMETRIC PREDICTORS OF QUALITY OF LIFE AT THREE YEAR LONGITUDINAL FOLLOW UP OF A FIRST EPISODE PSYCHOSIS COHORT

2012 ◽  
Vol 136 ◽  
pp. S273
Author(s):  
Shane J. Mclnerney ◽  
Cathy Scanlon ◽  
John McFarland ◽  
Heike Schmidt ◽  
Mohamed Ahmed ◽  
...  
Keyword(s):  
Quality Of Life ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis

487. Clinical and Morphometric Predictors of Quality of Life at Three Year Longitudinal Follow up of a First Episode Psychosis Cohort

2017 ◽  
Vol 81 (10) ◽  
pp. S198
Author(s):  
Shane McInerney ◽  
Cathy Scanlon ◽  
John McFarland ◽  
Heike Anderson-Schmidt ◽  
Dara Cannon ◽  
...  
Keyword(s):  
Quality Of Life ◽  
First Episode Psychosis ◽  
First Episode ◽  
Episode Psychosis

scholarly journals A nutrition intervention is effective in improving dietary components linked to cardiometabolic risk in youth with first-episode psychosis

2016 ◽  
Vol 115 (11) ◽  
pp. 1987-1993 ◽  
Author(s):  
Scott B. Teasdale ◽  
Philip B. Ward ◽  
Simon Rosenbaum ◽  
Andrew Watkins ◽  
Jackie Curtis ◽  
...  
Keyword(s):  
Mental Illness ◽  
Severe Mental Illness ◽  
Diet Quality ◽  
Dietary Intervention ◽  
Vegetable Intake ◽  
First Episode Psychosis ◽  
Nutrition Intervention ◽  
Cardiometabolic Disease ◽  
First Episode ◽  
Episode Psychosis

AbstractSevere mental illness is characterised by a 20-year mortality gap due to cardiometabolic disease. Poor diet in those with severe mental illness is an important and modifiable risk factor. The present study aimed to (i) examine baseline nutritional intake in youth with first-episode psychosis (FEP), (ii) evaluate the feasibility and acceptability of nutritional intervention early in FEP and (iii) to evaluate the effectiveness of early dietary intervention on key nutritional end points. Participants were recruited over a 12-month period from a community-based programme specifically targeting young people aged 15–25 years with newly diagnosed FEP. Individual dietetic consultations and practical group sessions were offered as part of a broader lifestyle programme. Dietary assessments were conducted before and at the end of the 12-week intervention. Participants exceeded recommended energy and Na intakes at baseline. Retention within the nutrition intervention was 67 %, consistent with other interventions offered to FEP clients. There was a 47 % reduction in discretionary food intake (−94 g/d,P<0·001) and reductions in daily energy (−24 %,P<0·001) and Na (−26 %,P<0·001) intakes. Diet quality significantly improved, and the mean change was 3·6 (95 % CI 0·2, 6·9,P<0·05), although this finding was not significant after Bonferroni’s correction. Increased vegetable intake was the main factor contributing to improved diet quality. Nutrition intervention delivered shortly after initiation of antipsychotic medication is feasible, acceptable and effective in youth with FEP. Strategies to prevent weight gain and metabolic decline will contribute to prevent premature cardiometabolic disease in this vulnerable population.

Subjective quality of life in first-episode psychosis. A ten year follow-up study

2016 ◽  
Vol 172 (1-3) ◽  
pp. 23-28 ◽  
Author(s):  
Erlend Strand Gardsjord ◽  
Kristin Lie Romm ◽  
Svein Friis ◽  
Helene Eidsmo Barder ◽  
Julie Evensen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
First Episode Psychosis ◽  
Subjective Quality ◽  
First Episode ◽  
Subjective Quality Of Life ◽  
Follow Up Study ◽  
Episode Psychosis

scholarly journals S228. SOCIAL AND OCCUPATIONAL FUNCTIONING AND SATISFACTION WITH CARE IN FINNISH FIRST-EPISODE PSYCHOSIS PATIENTS

2020 ◽  
Vol 46 (Supplement_1) ◽  
pp. S125-S125
Author(s):  
Paula Barrientos ◽  
Jaana Suvisaari ◽  
Tuula Kieseppä
Keyword(s):  
Patient Satisfaction ◽  
Psychotic Disorders ◽  
First Episode Psychosis ◽  
Diagnostic Interview ◽  
First Episode ◽  
Satisfaction With Care ◽  
Episode Psychosis ◽  
Psychiatric Staff

Abstract Background Patient satisfaction with care (PSC) is a valuable predictor in both quality of life and treatment outcomes with psychiatric patients. First episode psychosis (FEP) patients are a diverse group of usually young adults. Determining the factors behind PSC in FEP patients could be an important tool in planning better care programs and predictive tools for the outcome of FEP. Many FEP patients are still on the cusp of their adult lives. Achieving better treatment adherence by higher PSC could help many people back to their studies or work lives and enhance their quality of life and social and occupational functioning. Determining background factors and associations with better PSC would help tailoring treatment options for FEP patients. Methods The Helsinki Early Psychosis Study recruited FEP patients (aged 18 to 40 years old) who were having their first treatment of psychosis in the catchment area of the Helsinki University Hospital and the psychiatric services of Helsinki City in the time period from December 2010 to June 2016. The diagnoses of psychotic disorders were later verified using the Structured Diagnostic Interview for DSM-IV, Research Version, as well as a review of all medical records. Substance-induced psychotic disorders and psychotic disorders due to a general medical condition were excluded. Baseline assessment was conducted as soon as the patient had entered treatment and was able to give informed consent according to the treating personnel. Follow ups were conducted at 2 months after baseline. Data was gathered on symptoms, sociodemographic factors, functioning, overall health, aspects of treatment and medication. Duration of untreated psychosis was determined as accurately as possible with the help of patient records and diagnostic interview. Patient satisfaction was evaluated by PSQ (Patient satisfaction questionnaire) developed by Swedish researchers for their early intervention program for first episode psychosis patients. The questionnaire contains ten questions about different aspects of the patients’ care and was part of the 2-month follow-up protocol. Results 97 patients were recruited in the study. Out of those patients, 72 patients participated in the 2-month follow up and 51 filled out the PSC questionnaire. The results of the PSQ were translated into a dichotomist scale of “satisfied” (very or rather satisfied) or “not satisfied” (neither satisfied nor dissatisfied; rather or very dissatisfied). Interestingly, DUP was not associated with higher or lower satisfaction with care unlike in other studies. Conversely, higher SOFAS score at the 2-month follow up was associated with better treatment satisfaction. Especially patients who felt they had been able to influence their care, who felt that the sessions with the psychiatric staff been helpful, and who were satisfied with the concern and understanding the psychiatric staff had shown had significantly higher SOFAS than those who were not satisfied with these aspects of care, whereas e.g. attitudes regarding medication were not significantly associated with SOFAS. A summary score of the PSQ correlated positively with the 2 month SOFAS scores (Spearman rho 0.40, p=0.007). Discussion Unlike in many other studies, longer DUP was not associated with poorer PSC. Instead, satisfaction with qualitative aspects of treatment contact and being able to influence treatment decisions were associated with better functioning. This suggest that the staff-patient relationship and empowering patients in treatment decisions are important in the treatment of FEP.

Sign in / Sign up

Export Citation Format

Share Document